Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) currently has an Average Broker Rating of 1.73. This number is based on the 15 sell-side firms polled by Zacks. The ABR rank within the industry stands at 12. Analysts on a consensus basis are expecting that the stock will reach $136.43 within the year.
Many traders will build a system to use when entering the market. Many trading systems will work for a time, but they may need to be tweaked at some point in order to adapt to the current market environment. Successful trading systems usually require a great deal of discipline. The best traders are often able to become highly skilled at managing risk and securing profits. For new traders, it may be tempting to use a system that a friend or colleague recommends. This may work for some, but many individuals might eventually realize that the style or system does not particularly suit their trading style.
Research analysts are predicting that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will report earnings of $-1.36 per share when the firm issues their next quarterly report. This is the consensus earnings per share number according to data from Zack’s Research.
Most recently Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted quarterly earnings of $-1.06 which compared to the sell-side estimates of -1.23. The stock’s 12-month trailing earnings per share stands at $-4.7. Shares have moved $-1.91 over the past month and more recently, $-2.61 over the past week heading into the earnings announcement. There are 8 analyst projections that were taken into consideration from respected brokerage firms.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed the last session at $128.01 and sees an average of 1450033.75 shares trade hands in each session. The 52-week low of the stock stands at $36.88 while the current level stands at 88.39% of the 52-week High-Low range. Looking further out we can see that the stock has moved 62.7% over the past 12 weeks and 241.91% year to date.
11 analysts rate Alnylam Pharmaceuticals, Inc. a Buy or Strong Buy, which is 73.33% of all the analyst ratings.
This article is informational purposes only and should not be considered a recommendation to buy or sell the stock.